0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Biopharmaceutical CXO Market Research Report 2024
Published Date: November 2024
|
Report Code: QYRE-Auto-20N18646
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Biopharmaceutical CXO Market Research Report 2024
BUY CHAPTERS

Global Biopharmaceutical CXO Market Research Report 2024

Code: QYRE-Auto-20N18646
Report
November 2024
Pages:124
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Biopharmaceutical CXO Market Size

The global Biopharmaceutical CXO market was valued at US$ 54540 million in 2023 and is anticipated to reach US$ 96550 million by 2030, witnessing a CAGR of 8.5% during the forecast period 2024-2030.

Biopharmaceutical CXO Market

Biopharmaceutical CXO Market

Biopharmaceutical CXO services have gained significant importance as the complexity of biologics and biosimilars development continues to grow. By outsourcing specialized tasks such as clinical trials, process development, and large-scale biologic manufacturing, biopharmaceutical companies can focus on core innovations and strategic growth. This collaboration not only streamlines the drug development pipeline but also ensures compliance with regulatory standards, enhancing the overall efficiency and reducing time-to-market for breakthrough biologic therapies.
North American market for Biopharmaceutical CXO is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Biopharmaceutical CXO is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Biopharmaceutical CXO in API CXO is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Biopharmaceutical CXO include Catalent, Thermo Fisher Scientific, Lonza, Siegfried, Recipharm, Boehringer Ingelheim, WuXi AppTech, WuXi Biologics, Fareva, Samsung Biologics, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Biopharmaceutical CXO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biopharmaceutical CXO.
The Biopharmaceutical CXO market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Biopharmaceutical CXO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biopharmaceutical CXO companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Biopharmaceutical CXO Market Report

Report Metric Details
Report Name Biopharmaceutical CXO Market
Accounted market size in 2023 US$ 54540 million
Forecasted market size in 2030 US$ 96550 million
CAGR 8.5%
Base Year 2023
Forecasted years 2024 - 2030
Segment by Type
  • CRO
  • CDMO/CMO
  • CSO
Segment by Application
  • API CXO
  • FDF CXO
  • Other
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Catalent, Thermo Fisher Scientific, Lonza, Siegfried, Recipharm, Boehringer Ingelheim, WuXi AppTech, WuXi Biologics, Fareva, Samsung Biologics, Aenova, Delpharm, Strides Pharma, Piramal, Famar, Curia, Jubilant, Vetter, AGC Pharma Chemicals, Asymchem, Pharmaron, Eurofins, Ascendia Pharmaceuticals, Ardena, CPL, UPM Pharmaceuticals, FUJIFILM Diosynth Biotechnologies, Groupe Parima, TBD Pharmatech, Avid Bioservices, NextPharma, Alcami, Societal CDMO, MedPharm, Euroapi, BioVectra, Pfizer CentreOne, Fermion
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Biopharmaceutical CXO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Biopharmaceutical CXO Market growing?

Ans: The Biopharmaceutical CXO Market witnessing a CAGR of 8.5% during the forecast period 2024-2030.

What is the Biopharmaceutical CXO Market size in 2030?

Ans: The Biopharmaceutical CXO Market size in 2030 will be US$ 96550 million.

Who are the main players in the Biopharmaceutical CXO Market report?

Ans: The main players in the Biopharmaceutical CXO Market are Catalent, Thermo Fisher Scientific, Lonza, Siegfried, Recipharm, Boehringer Ingelheim, WuXi AppTech, WuXi Biologics, Fareva, Samsung Biologics, Aenova, Delpharm, Strides Pharma, Piramal, Famar, Curia, Jubilant, Vetter, AGC Pharma Chemicals, Asymchem, Pharmaron, Eurofins, Ascendia Pharmaceuticals, Ardena, CPL, UPM Pharmaceuticals, FUJIFILM Diosynth Biotechnologies, Groupe Parima, TBD Pharmatech, Avid Bioservices, NextPharma, Alcami, Societal CDMO, MedPharm, Euroapi, BioVectra, Pfizer CentreOne, Fermion

What are the Application segmentation covered in the Biopharmaceutical CXO Market report?

Ans: The Applications covered in the Biopharmaceutical CXO Market report are API CXO, FDF CXO, Other

What are the Type segmentation covered in the Biopharmaceutical CXO Market report?

Ans: The Types covered in the Biopharmaceutical CXO Market report are CRO, CDMO/CMO, CSO

Recommended Reports

APIs & Ingredients

Biopharma Manufacturing

Biopharma Logistics & Equipment

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Biopharmaceutical CXO Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 CRO
1.2.3 CDMO/CMO
1.2.4 CSO
1.3 Market by Application
1.3.1 Global Biopharmaceutical CXO Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 API CXO
1.3.3 FDF CXO
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Biopharmaceutical CXO Market Perspective (2019-2030)
2.2 Global Biopharmaceutical CXO Growth Trends by Region
2.2.1 Global Biopharmaceutical CXO Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Biopharmaceutical CXO Historic Market Size by Region (2019-2024)
2.2.3 Biopharmaceutical CXO Forecasted Market Size by Region (2025-2030)
2.3 Biopharmaceutical CXO Market Dynamics
2.3.1 Biopharmaceutical CXO Industry Trends
2.3.2 Biopharmaceutical CXO Market Drivers
2.3.3 Biopharmaceutical CXO Market Challenges
2.3.4 Biopharmaceutical CXO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Biopharmaceutical CXO Players by Revenue
3.1.1 Global Top Biopharmaceutical CXO Players by Revenue (2019-2024)
3.1.2 Global Biopharmaceutical CXO Revenue Market Share by Players (2019-2024)
3.2 Global Biopharmaceutical CXO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Biopharmaceutical CXO Revenue
3.4 Global Biopharmaceutical CXO Market Concentration Ratio
3.4.1 Global Biopharmaceutical CXO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Biopharmaceutical CXO Revenue in 2023
3.5 Global Key Players of Biopharmaceutical CXO Head office and Area Served
3.6 Global Key Players of Biopharmaceutical CXO, Product and Application
3.7 Global Key Players of Biopharmaceutical CXO, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Biopharmaceutical CXO Breakdown Data by Type
4.1 Global Biopharmaceutical CXO Historic Market Size by Type (2019-2024)
4.2 Global Biopharmaceutical CXO Forecasted Market Size by Type (2025-2030)
5 Biopharmaceutical CXO Breakdown Data by Application
5.1 Global Biopharmaceutical CXO Historic Market Size by Application (2019-2024)
5.2 Global Biopharmaceutical CXO Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Biopharmaceutical CXO Market Size (2019-2030)
6.2 North America Biopharmaceutical CXO Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Biopharmaceutical CXO Market Size by Country (2019-2024)
6.4 North America Biopharmaceutical CXO Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Biopharmaceutical CXO Market Size (2019-2030)
7.2 Europe Biopharmaceutical CXO Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Biopharmaceutical CXO Market Size by Country (2019-2024)
7.4 Europe Biopharmaceutical CXO Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Biopharmaceutical CXO Market Size (2019-2030)
8.2 Asia-Pacific Biopharmaceutical CXO Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Biopharmaceutical CXO Market Size by Region (2019-2024)
8.4 Asia-Pacific Biopharmaceutical CXO Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Biopharmaceutical CXO Market Size (2019-2030)
9.2 Latin America Biopharmaceutical CXO Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Biopharmaceutical CXO Market Size by Country (2019-2024)
9.4 Latin America Biopharmaceutical CXO Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Biopharmaceutical CXO Market Size (2019-2030)
10.2 Middle East & Africa Biopharmaceutical CXO Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Biopharmaceutical CXO Market Size by Country (2019-2024)
10.4 Middle East & Africa Biopharmaceutical CXO Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Catalent
11.1.1 Catalent Company Details
11.1.2 Catalent Business Overview
11.1.3 Catalent Biopharmaceutical CXO Introduction
11.1.4 Catalent Revenue in Biopharmaceutical CXO Business (2019-2024)
11.1.5 Catalent Recent Development
11.2 Thermo Fisher Scientific
11.2.1 Thermo Fisher Scientific Company Details
11.2.2 Thermo Fisher Scientific Business Overview
11.2.3 Thermo Fisher Scientific Biopharmaceutical CXO Introduction
11.2.4 Thermo Fisher Scientific Revenue in Biopharmaceutical CXO Business (2019-2024)
11.2.5 Thermo Fisher Scientific Recent Development
11.3 Lonza
11.3.1 Lonza Company Details
11.3.2 Lonza Business Overview
11.3.3 Lonza Biopharmaceutical CXO Introduction
11.3.4 Lonza Revenue in Biopharmaceutical CXO Business (2019-2024)
11.3.5 Lonza Recent Development
11.4 Siegfried
11.4.1 Siegfried Company Details
11.4.2 Siegfried Business Overview
11.4.3 Siegfried Biopharmaceutical CXO Introduction
11.4.4 Siegfried Revenue in Biopharmaceutical CXO Business (2019-2024)
11.4.5 Siegfried Recent Development
11.5 Recipharm
11.5.1 Recipharm Company Details
11.5.2 Recipharm Business Overview
11.5.3 Recipharm Biopharmaceutical CXO Introduction
11.5.4 Recipharm Revenue in Biopharmaceutical CXO Business (2019-2024)
11.5.5 Recipharm Recent Development
11.6 Boehringer Ingelheim
11.6.1 Boehringer Ingelheim Company Details
11.6.2 Boehringer Ingelheim Business Overview
11.6.3 Boehringer Ingelheim Biopharmaceutical CXO Introduction
11.6.4 Boehringer Ingelheim Revenue in Biopharmaceutical CXO Business (2019-2024)
11.6.5 Boehringer Ingelheim Recent Development
11.7 WuXi AppTech
11.7.1 WuXi AppTech Company Details
11.7.2 WuXi AppTech Business Overview
11.7.3 WuXi AppTech Biopharmaceutical CXO Introduction
11.7.4 WuXi AppTech Revenue in Biopharmaceutical CXO Business (2019-2024)
11.7.5 WuXi AppTech Recent Development
11.8 WuXi Biologics
11.8.1 WuXi Biologics Company Details
11.8.2 WuXi Biologics Business Overview
11.8.3 WuXi Biologics Biopharmaceutical CXO Introduction
11.8.4 WuXi Biologics Revenue in Biopharmaceutical CXO Business (2019-2024)
11.8.5 WuXi Biologics Recent Development
11.9 Fareva
11.9.1 Fareva Company Details
11.9.2 Fareva Business Overview
11.9.3 Fareva Biopharmaceutical CXO Introduction
11.9.4 Fareva Revenue in Biopharmaceutical CXO Business (2019-2024)
11.9.5 Fareva Recent Development
11.10 Samsung Biologics
11.10.1 Samsung Biologics Company Details
11.10.2 Samsung Biologics Business Overview
11.10.3 Samsung Biologics Biopharmaceutical CXO Introduction
11.10.4 Samsung Biologics Revenue in Biopharmaceutical CXO Business (2019-2024)
11.10.5 Samsung Biologics Recent Development
11.11 Aenova
11.11.1 Aenova Company Details
11.11.2 Aenova Business Overview
11.11.3 Aenova Biopharmaceutical CXO Introduction
11.11.4 Aenova Revenue in Biopharmaceutical CXO Business (2019-2024)
11.11.5 Aenova Recent Development
11.12 Delpharm
11.12.1 Delpharm Company Details
11.12.2 Delpharm Business Overview
11.12.3 Delpharm Biopharmaceutical CXO Introduction
11.12.4 Delpharm Revenue in Biopharmaceutical CXO Business (2019-2024)
11.12.5 Delpharm Recent Development
11.13 Strides Pharma
11.13.1 Strides Pharma Company Details
11.13.2 Strides Pharma Business Overview
11.13.3 Strides Pharma Biopharmaceutical CXO Introduction
11.13.4 Strides Pharma Revenue in Biopharmaceutical CXO Business (2019-2024)
11.13.5 Strides Pharma Recent Development
11.14 Piramal
11.14.1 Piramal Company Details
11.14.2 Piramal Business Overview
11.14.3 Piramal Biopharmaceutical CXO Introduction
11.14.4 Piramal Revenue in Biopharmaceutical CXO Business (2019-2024)
11.14.5 Piramal Recent Development
11.15 Famar
11.15.1 Famar Company Details
11.15.2 Famar Business Overview
11.15.3 Famar Biopharmaceutical CXO Introduction
11.15.4 Famar Revenue in Biopharmaceutical CXO Business (2019-2024)
11.15.5 Famar Recent Development
11.16 Curia
11.16.1 Curia Company Details
11.16.2 Curia Business Overview
11.16.3 Curia Biopharmaceutical CXO Introduction
11.16.4 Curia Revenue in Biopharmaceutical CXO Business (2019-2024)
11.16.5 Curia Recent Development
11.17 Jubilant
11.17.1 Jubilant Company Details
11.17.2 Jubilant Business Overview
11.17.3 Jubilant Biopharmaceutical CXO Introduction
11.17.4 Jubilant Revenue in Biopharmaceutical CXO Business (2019-2024)
11.17.5 Jubilant Recent Development
11.18 Vetter
11.18.1 Vetter Company Details
11.18.2 Vetter Business Overview
11.18.3 Vetter Biopharmaceutical CXO Introduction
11.18.4 Vetter Revenue in Biopharmaceutical CXO Business (2019-2024)
11.18.5 Vetter Recent Development
11.19 AGC Pharma Chemicals
11.19.1 AGC Pharma Chemicals Company Details
11.19.2 AGC Pharma Chemicals Business Overview
11.19.3 AGC Pharma Chemicals Biopharmaceutical CXO Introduction
11.19.4 AGC Pharma Chemicals Revenue in Biopharmaceutical CXO Business (2019-2024)
11.19.5 AGC Pharma Chemicals Recent Development
11.20 Asymchem
11.20.1 Asymchem Company Details
11.20.2 Asymchem Business Overview
11.20.3 Asymchem Biopharmaceutical CXO Introduction
11.20.4 Asymchem Revenue in Biopharmaceutical CXO Business (2019-2024)
11.20.5 Asymchem Recent Development
11.21 Pharmaron
11.21.1 Pharmaron Company Details
11.21.2 Pharmaron Business Overview
11.21.3 Pharmaron Biopharmaceutical CXO Introduction
11.21.4 Pharmaron Revenue in Biopharmaceutical CXO Business (2019-2024)
11.21.5 Pharmaron Recent Development
11.22 Eurofins
11.22.1 Eurofins Company Details
11.22.2 Eurofins Business Overview
11.22.3 Eurofins Biopharmaceutical CXO Introduction
11.22.4 Eurofins Revenue in Biopharmaceutical CXO Business (2019-2024)
11.22.5 Eurofins Recent Development
11.23 Ascendia Pharmaceuticals
11.23.1 Ascendia Pharmaceuticals Company Details
11.23.2 Ascendia Pharmaceuticals Business Overview
11.23.3 Ascendia Pharmaceuticals Biopharmaceutical CXO Introduction
11.23.4 Ascendia Pharmaceuticals Revenue in Biopharmaceutical CXO Business (2019-2024)
11.23.5 Ascendia Pharmaceuticals Recent Development
11.24 Ardena
11.24.1 Ardena Company Details
11.24.2 Ardena Business Overview
11.24.3 Ardena Biopharmaceutical CXO Introduction
11.24.4 Ardena Revenue in Biopharmaceutical CXO Business (2019-2024)
11.24.5 Ardena Recent Development
11.25 CPL
11.25.1 CPL Company Details
11.25.2 CPL Business Overview
11.25.3 CPL Biopharmaceutical CXO Introduction
11.25.4 CPL Revenue in Biopharmaceutical CXO Business (2019-2024)
11.25.5 CPL Recent Development
11.26 UPM Pharmaceuticals
11.26.1 UPM Pharmaceuticals Company Details
11.26.2 UPM Pharmaceuticals Business Overview
11.26.3 UPM Pharmaceuticals Biopharmaceutical CXO Introduction
11.26.4 UPM Pharmaceuticals Revenue in Biopharmaceutical CXO Business (2019-2024)
11.26.5 UPM Pharmaceuticals Recent Development
11.27 FUJIFILM Diosynth Biotechnologies
11.27.1 FUJIFILM Diosynth Biotechnologies Company Details
11.27.2 FUJIFILM Diosynth Biotechnologies Business Overview
11.27.3 FUJIFILM Diosynth Biotechnologies Biopharmaceutical CXO Introduction
11.27.4 FUJIFILM Diosynth Biotechnologies Revenue in Biopharmaceutical CXO Business (2019-2024)
11.27.5 FUJIFILM Diosynth Biotechnologies Recent Development
11.28 Groupe Parima
11.28.1 Groupe Parima Company Details
11.28.2 Groupe Parima Business Overview
11.28.3 Groupe Parima Biopharmaceutical CXO Introduction
11.28.4 Groupe Parima Revenue in Biopharmaceutical CXO Business (2019-2024)
11.28.5 Groupe Parima Recent Development
11.29 TBD Pharmatech
11.29.1 TBD Pharmatech Company Details
11.29.2 TBD Pharmatech Business Overview
11.29.3 TBD Pharmatech Biopharmaceutical CXO Introduction
11.29.4 TBD Pharmatech Revenue in Biopharmaceutical CXO Business (2019-2024)
11.29.5 TBD Pharmatech Recent Development
11.30 Avid Bioservices
11.30.1 Avid Bioservices Company Details
11.30.2 Avid Bioservices Business Overview
11.30.3 Avid Bioservices Biopharmaceutical CXO Introduction
11.30.4 Avid Bioservices Revenue in Biopharmaceutical CXO Business (2019-2024)
11.30.5 Avid Bioservices Recent Development
11.31 NextPharma
11.31.1 NextPharma Company Details
11.31.2 NextPharma Business Overview
11.31.3 NextPharma Biopharmaceutical CXO Introduction
11.31.4 NextPharma Revenue in Biopharmaceutical CXO Business (2019-2024)
11.31.5 NextPharma Recent Development
11.32 Alcami
11.32.1 Alcami Company Details
11.32.2 Alcami Business Overview
11.32.3 Alcami Biopharmaceutical CXO Introduction
11.32.4 Alcami Revenue in Biopharmaceutical CXO Business (2019-2024)
11.32.5 Alcami Recent Development
11.33 Societal CDMO
11.33.1 Societal CDMO Company Details
11.33.2 Societal CDMO Business Overview
11.33.3 Societal CDMO Biopharmaceutical CXO Introduction
11.33.4 Societal CDMO Revenue in Biopharmaceutical CXO Business (2019-2024)
11.33.5 Societal CDMO Recent Development
11.34 MedPharm
11.34.1 MedPharm Company Details
11.34.2 MedPharm Business Overview
11.34.3 MedPharm Biopharmaceutical CXO Introduction
11.34.4 MedPharm Revenue in Biopharmaceutical CXO Business (2019-2024)
11.34.5 MedPharm Recent Development
11.35 Euroapi
11.35.1 Euroapi Company Details
11.35.2 Euroapi Business Overview
11.35.3 Euroapi Biopharmaceutical CXO Introduction
11.35.4 Euroapi Revenue in Biopharmaceutical CXO Business (2019-2024)
11.35.5 Euroapi Recent Development
11.36 BioVectra
11.36.1 BioVectra Company Details
11.36.2 BioVectra Business Overview
11.36.3 BioVectra Biopharmaceutical CXO Introduction
11.36.4 BioVectra Revenue in Biopharmaceutical CXO Business (2019-2024)
11.36.5 BioVectra Recent Development
11.37 Pfizer CentreOne
11.37.1 Pfizer CentreOne Company Details
11.37.2 Pfizer CentreOne Business Overview
11.37.3 Pfizer CentreOne Biopharmaceutical CXO Introduction
11.37.4 Pfizer CentreOne Revenue in Biopharmaceutical CXO Business (2019-2024)
11.37.5 Pfizer CentreOne Recent Development
11.38 Fermion
11.38.1 Fermion Company Details
11.38.2 Fermion Business Overview
11.38.3 Fermion Biopharmaceutical CXO Introduction
11.38.4 Fermion Revenue in Biopharmaceutical CXO Business (2019-2024)
11.38.5 Fermion Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
 Table 1. Global Biopharmaceutical CXO Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
 Table 2. Key Players of CRO
 Table 3. Key Players of CDMO/CMO
 Table 4. Key Players of CSO
 Table 5. Global Biopharmaceutical CXO Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
 Table 6. Global Biopharmaceutical CXO Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Table 7. Global Biopharmaceutical CXO Market Size by Region (2019-2024) & (US$ Million)
 Table 8. Global Biopharmaceutical CXO Market Share by Region (2019-2024)
 Table 9. Global Biopharmaceutical CXO Forecasted Market Size by Region (2025-2030) & (US$ Million)
 Table 10. Global Biopharmaceutical CXO Market Share by Region (2025-2030)
 Table 11. Biopharmaceutical CXO Market Trends
 Table 12. Biopharmaceutical CXO Market Drivers
 Table 13. Biopharmaceutical CXO Market Challenges
 Table 14. Biopharmaceutical CXO Market Restraints
 Table 15. Global Biopharmaceutical CXO Revenue by Players (2019-2024) & (US$ Million)
 Table 16. Global Biopharmaceutical CXO Market Share by Players (2019-2024)
 Table 17. Global Top Biopharmaceutical CXO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biopharmaceutical CXO as of 2023)
 Table 18. Ranking of Global Top Biopharmaceutical CXO Companies by Revenue (US$ Million) in 2023
 Table 19. Global 5 Largest Players Market Share by Biopharmaceutical CXO Revenue (CR5 and HHI) & (2019-2024)
 Table 20. Global Key Players of Biopharmaceutical CXO, Headquarters and Area Served
 Table 21. Global Key Players of Biopharmaceutical CXO, Product and Application
 Table 22. Global Key Players of Biopharmaceutical CXO, Date of Enter into This Industry
 Table 23. Mergers & Acquisitions, Expansion Plans
 Table 24. Global Biopharmaceutical CXO Market Size by Type (2019-2024) & (US$ Million)
 Table 25. Global Biopharmaceutical CXO Revenue Market Share by Type (2019-2024)
 Table 26. Global Biopharmaceutical CXO Forecasted Market Size by Type (2025-2030) & (US$ Million)
 Table 27. Global Biopharmaceutical CXO Revenue Market Share by Type (2025-2030)
 Table 28. Global Biopharmaceutical CXO Market Size by Application (2019-2024) & (US$ Million)
 Table 29. Global Biopharmaceutical CXO Revenue Market Share by Application (2019-2024)
 Table 30. Global Biopharmaceutical CXO Forecasted Market Size by Application (2025-2030) & (US$ Million)
 Table 31. Global Biopharmaceutical CXO Revenue Market Share by Application (2025-2030)
 Table 32. North America Biopharmaceutical CXO Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
 Table 33. North America Biopharmaceutical CXO Market Size by Country (2019-2024) & (US$ Million)
 Table 34. North America Biopharmaceutical CXO Market Size by Country (2025-2030) & (US$ Million)
 Table 35. Europe Biopharmaceutical CXO Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
 Table 36. Europe Biopharmaceutical CXO Market Size by Country (2019-2024) & (US$ Million)
 Table 37. Europe Biopharmaceutical CXO Market Size by Country (2025-2030) & (US$ Million)
 Table 38. Asia-Pacific Biopharmaceutical CXO Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
 Table 39. Asia-Pacific Biopharmaceutical CXO Market Size by Region (2019-2024) & (US$ Million)
 Table 40. Asia-Pacific Biopharmaceutical CXO Market Size by Region (2025-2030) & (US$ Million)
 Table 41. Latin America Biopharmaceutical CXO Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
 Table 42. Latin America Biopharmaceutical CXO Market Size by Country (2019-2024) & (US$ Million)
 Table 43. Latin America Biopharmaceutical CXO Market Size by Country (2025-2030) & (US$ Million)
 Table 44. Middle East & Africa Biopharmaceutical CXO Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
 Table 45. Middle East & Africa Biopharmaceutical CXO Market Size by Country (2019-2024) & (US$ Million)
 Table 46. Middle East & Africa Biopharmaceutical CXO Market Size by Country (2025-2030) & (US$ Million)
 Table 47. Catalent Company Details
 Table 48. Catalent Business Overview
 Table 49. Catalent Biopharmaceutical CXO Product
 Table 50. Catalent Revenue in Biopharmaceutical CXO Business (2019-2024) & (US$ Million)
 Table 51. Catalent Recent Development
 Table 52. Thermo Fisher Scientific Company Details
 Table 53. Thermo Fisher Scientific Business Overview
 Table 54. Thermo Fisher Scientific Biopharmaceutical CXO Product
 Table 55. Thermo Fisher Scientific Revenue in Biopharmaceutical CXO Business (2019-2024) & (US$ Million)
 Table 56. Thermo Fisher Scientific Recent Development
 Table 57. Lonza Company Details
 Table 58. Lonza Business Overview
 Table 59. Lonza Biopharmaceutical CXO Product
 Table 60. Lonza Revenue in Biopharmaceutical CXO Business (2019-2024) & (US$ Million)
 Table 61. Lonza Recent Development
 Table 62. Siegfried Company Details
 Table 63. Siegfried Business Overview
 Table 64. Siegfried Biopharmaceutical CXO Product
 Table 65. Siegfried Revenue in Biopharmaceutical CXO Business (2019-2024) & (US$ Million)
 Table 66. Siegfried Recent Development
 Table 67. Recipharm Company Details
 Table 68. Recipharm Business Overview
 Table 69. Recipharm Biopharmaceutical CXO Product
 Table 70. Recipharm Revenue in Biopharmaceutical CXO Business (2019-2024) & (US$ Million)
 Table 71. Recipharm Recent Development
 Table 72. Boehringer Ingelheim Company Details
 Table 73. Boehringer Ingelheim Business Overview
 Table 74. Boehringer Ingelheim Biopharmaceutical CXO Product
 Table 75. Boehringer Ingelheim Revenue in Biopharmaceutical CXO Business (2019-2024) & (US$ Million)
 Table 76. Boehringer Ingelheim Recent Development
 Table 77. WuXi AppTech Company Details
 Table 78. WuXi AppTech Business Overview
 Table 79. WuXi AppTech Biopharmaceutical CXO Product
 Table 80. WuXi AppTech Revenue in Biopharmaceutical CXO Business (2019-2024) & (US$ Million)
 Table 81. WuXi AppTech Recent Development
 Table 82. WuXi Biologics Company Details
 Table 83. WuXi Biologics Business Overview
 Table 84. WuXi Biologics Biopharmaceutical CXO Product
 Table 85. WuXi Biologics Revenue in Biopharmaceutical CXO Business (2019-2024) & (US$ Million)
 Table 86. WuXi Biologics Recent Development
 Table 87. Fareva Company Details
 Table 88. Fareva Business Overview
 Table 89. Fareva Biopharmaceutical CXO Product
 Table 90. Fareva Revenue in Biopharmaceutical CXO Business (2019-2024) & (US$ Million)
 Table 91. Fareva Recent Development
 Table 92. Samsung Biologics Company Details
 Table 93. Samsung Biologics Business Overview
 Table 94. Samsung Biologics Biopharmaceutical CXO Product
 Table 95. Samsung Biologics Revenue in Biopharmaceutical CXO Business (2019-2024) & (US$ Million)
 Table 96. Samsung Biologics Recent Development
 Table 97. Aenova Company Details
 Table 98. Aenova Business Overview
 Table 99. Aenova Biopharmaceutical CXO Product
 Table 100. Aenova Revenue in Biopharmaceutical CXO Business (2019-2024) & (US$ Million)
 Table 101. Aenova Recent Development
 Table 102. Delpharm Company Details
 Table 103. Delpharm Business Overview
 Table 104. Delpharm Biopharmaceutical CXO Product
 Table 105. Delpharm Revenue in Biopharmaceutical CXO Business (2019-2024) & (US$ Million)
 Table 106. Delpharm Recent Development
 Table 107. Strides Pharma Company Details
 Table 108. Strides Pharma Business Overview
 Table 109. Strides Pharma Biopharmaceutical CXO Product
 Table 110. Strides Pharma Revenue in Biopharmaceutical CXO Business (2019-2024) & (US$ Million)
 Table 111. Strides Pharma Recent Development
 Table 112. Piramal Company Details
 Table 113. Piramal Business Overview
 Table 114. Piramal Biopharmaceutical CXO Product
 Table 115. Piramal Revenue in Biopharmaceutical CXO Business (2019-2024) & (US$ Million)
 Table 116. Piramal Recent Development
 Table 117. Famar Company Details
 Table 118. Famar Business Overview
 Table 119. Famar Biopharmaceutical CXO Product
 Table 120. Famar Revenue in Biopharmaceutical CXO Business (2019-2024) & (US$ Million)
 Table 121. Famar Recent Development
 Table 122. Curia Company Details
 Table 123. Curia Business Overview
 Table 124. Curia Biopharmaceutical CXO Product
 Table 125. Curia Revenue in Biopharmaceutical CXO Business (2019-2024) & (US$ Million)
 Table 126. Curia Recent Development
 Table 127. Jubilant Company Details
 Table 128. Jubilant Business Overview
 Table 129. Jubilant Biopharmaceutical CXO Product
 Table 130. Jubilant Revenue in Biopharmaceutical CXO Business (2019-2024) & (US$ Million)
 Table 131. Jubilant Recent Development
 Table 132. Vetter Company Details
 Table 133. Vetter Business Overview
 Table 134. Vetter Biopharmaceutical CXO Product
 Table 135. Vetter Revenue in Biopharmaceutical CXO Business (2019-2024) & (US$ Million)
 Table 136. Vetter Recent Development
 Table 137. AGC Pharma Chemicals Company Details
 Table 138. AGC Pharma Chemicals Business Overview
 Table 139. AGC Pharma Chemicals Biopharmaceutical CXO Product
 Table 140. AGC Pharma Chemicals Revenue in Biopharmaceutical CXO Business (2019-2024) & (US$ Million)
 Table 141. AGC Pharma Chemicals Recent Development
 Table 142. Asymchem Company Details
 Table 143. Asymchem Business Overview
 Table 144. Asymchem Biopharmaceutical CXO Product
 Table 145. Asymchem Revenue in Biopharmaceutical CXO Business (2019-2024) & (US$ Million)
 Table 146. Asymchem Recent Development
 Table 147. Pharmaron Company Details
 Table 148. Pharmaron Business Overview
 Table 149. Pharmaron Biopharmaceutical CXO Product
 Table 150. Pharmaron Revenue in Biopharmaceutical CXO Business (2019-2024) & (US$ Million)
 Table 151. Pharmaron Recent Development
 Table 152. Eurofins Company Details
 Table 153. Eurofins Business Overview
 Table 154. Eurofins Biopharmaceutical CXO Product
 Table 155. Eurofins Revenue in Biopharmaceutical CXO Business (2019-2024) & (US$ Million)
 Table 156. Eurofins Recent Development
 Table 157. Ascendia Pharmaceuticals Company Details
 Table 158. Ascendia Pharmaceuticals Business Overview
 Table 159. Ascendia Pharmaceuticals Biopharmaceutical CXO Product
 Table 160. Ascendia Pharmaceuticals Revenue in Biopharmaceutical CXO Business (2019-2024) & (US$ Million)
 Table 161. Ascendia Pharmaceuticals Recent Development
 Table 162. Ardena Company Details
 Table 163. Ardena Business Overview
 Table 164. Ardena Biopharmaceutical CXO Product
 Table 165. Ardena Revenue in Biopharmaceutical CXO Business (2019-2024) & (US$ Million)
 Table 166. Ardena Recent Development
 Table 167. CPL Company Details
 Table 168. CPL Business Overview
 Table 169. CPL Biopharmaceutical CXO Product
 Table 170. CPL Revenue in Biopharmaceutical CXO Business (2019-2024) & (US$ Million)
 Table 171. CPL Recent Development
 Table 172. UPM Pharmaceuticals Company Details
 Table 173. UPM Pharmaceuticals Business Overview
 Table 174. UPM Pharmaceuticals Biopharmaceutical CXO Product
 Table 175. UPM Pharmaceuticals Revenue in Biopharmaceutical CXO Business (2019-2024) & (US$ Million)
 Table 176. UPM Pharmaceuticals Recent Development
 Table 177. FUJIFILM Diosynth Biotechnologies Company Details
 Table 178. FUJIFILM Diosynth Biotechnologies Business Overview
 Table 179. FUJIFILM Diosynth Biotechnologies Biopharmaceutical CXO Product
 Table 180. FUJIFILM Diosynth Biotechnologies Revenue in Biopharmaceutical CXO Business (2019-2024) & (US$ Million)
 Table 181. FUJIFILM Diosynth Biotechnologies Recent Development
 Table 182. Groupe Parima Company Details
 Table 183. Groupe Parima Business Overview
 Table 184. Groupe Parima Biopharmaceutical CXO Product
 Table 185. Groupe Parima Revenue in Biopharmaceutical CXO Business (2019-2024) & (US$ Million)
 Table 186. Groupe Parima Recent Development
 Table 187. TBD Pharmatech Company Details
 Table 188. TBD Pharmatech Business Overview
 Table 189. TBD Pharmatech Biopharmaceutical CXO Product
 Table 190. TBD Pharmatech Revenue in Biopharmaceutical CXO Business (2019-2024) & (US$ Million)
 Table 191. TBD Pharmatech Recent Development
 Table 192. Avid Bioservices Company Details
 Table 193. Avid Bioservices Business Overview
 Table 194. Avid Bioservices Biopharmaceutical CXO Product
 Table 195. Avid Bioservices Revenue in Biopharmaceutical CXO Business (2019-2024) & (US$ Million)
 Table 196. Avid Bioservices Recent Development
 Table 197. NextPharma Company Details
 Table 198. NextPharma Business Overview
 Table 199. NextPharma Biopharmaceutical CXO Product
 Table 200. NextPharma Revenue in Biopharmaceutical CXO Business (2019-2024) & (US$ Million)
 Table 201. NextPharma Recent Development
 Table 202. Alcami Company Details
 Table 203. Alcami Business Overview
 Table 204. Alcami Biopharmaceutical CXO Product
 Table 205. Alcami Revenue in Biopharmaceutical CXO Business (2019-2024) & (US$ Million)
 Table 206. Alcami Recent Development
 Table 207. Societal CDMO Company Details
 Table 208. Societal CDMO Business Overview
 Table 209. Societal CDMO Biopharmaceutical CXO Product
 Table 210. Societal CDMO Revenue in Biopharmaceutical CXO Business (2019-2024) & (US$ Million)
 Table 211. Societal CDMO Recent Development
 Table 212. MedPharm Company Details
 Table 213. MedPharm Business Overview
 Table 214. MedPharm Biopharmaceutical CXO Product
 Table 215. MedPharm Revenue in Biopharmaceutical CXO Business (2019-2024) & (US$ Million)
 Table 216. MedPharm Recent Development
 Table 217. Euroapi Company Details
 Table 218. Euroapi Business Overview
 Table 219. Euroapi Biopharmaceutical CXO Product
 Table 220. Euroapi Revenue in Biopharmaceutical CXO Business (2019-2024) & (US$ Million)
 Table 221. Euroapi Recent Development
 Table 222. BioVectra Company Details
 Table 223. BioVectra Business Overview
 Table 224. BioVectra Biopharmaceutical CXO Product
 Table 225. BioVectra Revenue in Biopharmaceutical CXO Business (2019-2024) & (US$ Million)
 Table 226. BioVectra Recent Development
 Table 227. Pfizer CentreOne Company Details
 Table 228. Pfizer CentreOne Business Overview
 Table 229. Pfizer CentreOne Biopharmaceutical CXO Product
 Table 230. Pfizer CentreOne Revenue in Biopharmaceutical CXO Business (2019-2024) & (US$ Million)
 Table 231. Pfizer CentreOne Recent Development
 Table 232. Fermion Company Details
 Table 233. Fermion Business Overview
 Table 234. Fermion Biopharmaceutical CXO Product
 Table 235. Fermion Revenue in Biopharmaceutical CXO Business (2019-2024) & (US$ Million)
 Table 236. Fermion Recent Development
 Table 237. Research Programs/Design for This Report
 Table 238. Key Data Information from Secondary Sources
 Table 239. Key Data Information from Primary Sources
 Table 240. Authors List of This Report


List of Figures
 Figure 1. Biopharmaceutical CXO Picture
 Figure 2. Global Biopharmaceutical CXO Market Size Comparison by Type (2024-2030) & (US$ Million)
 Figure 3. Global Biopharmaceutical CXO Market Share by Type: 2023 VS 2030
 Figure 4. CRO Features
 Figure 5. CDMO/CMO Features
 Figure 6. CSO Features
 Figure 7. Global Biopharmaceutical CXO Market Size by Application (2024-2030) & (US$ Million)
 Figure 8. Global Biopharmaceutical CXO Market Share by Application: 2023 VS 2030
 Figure 9. API CXO Case Studies
 Figure 10. FDF CXO Case Studies
 Figure 11. Other Case Studies
 Figure 12. Biopharmaceutical CXO Report Years Considered
 Figure 13. Global Biopharmaceutical CXO Market Size (US$ Million), Year-over-Year: 2019-2030
 Figure 14. Global Biopharmaceutical CXO Market Size, (US$ Million), 2019 VS 2023 VS 2030
 Figure 15. Global Biopharmaceutical CXO Market Share by Region: 2023 VS 2030
 Figure 16. Global Biopharmaceutical CXO Market Share by Players in 2023
 Figure 17. Global Top Biopharmaceutical CXO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biopharmaceutical CXO as of 2023)
 Figure 18. The Top 10 and 5 Players Market Share by Biopharmaceutical CXO Revenue in 2023
 Figure 19. North America Biopharmaceutical CXO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 20. North America Biopharmaceutical CXO Market Share by Country (2019-2030)
 Figure 21. United States Biopharmaceutical CXO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 22. Canada Biopharmaceutical CXO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 23. Europe Biopharmaceutical CXO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 24. Europe Biopharmaceutical CXO Market Share by Country (2019-2030)
 Figure 25. Germany Biopharmaceutical CXO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 26. France Biopharmaceutical CXO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 27. U.K. Biopharmaceutical CXO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 28. Italy Biopharmaceutical CXO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 29. Russia Biopharmaceutical CXO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 30. Nordic Countries Biopharmaceutical CXO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 31. Asia-Pacific Biopharmaceutical CXO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 32. Asia-Pacific Biopharmaceutical CXO Market Share by Region (2019-2030)
 Figure 33. China Biopharmaceutical CXO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 34. Japan Biopharmaceutical CXO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 35. South Korea Biopharmaceutical CXO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 36. Southeast Asia Biopharmaceutical CXO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 37. India Biopharmaceutical CXO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 38. Australia Biopharmaceutical CXO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 39. Latin America Biopharmaceutical CXO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 40. Latin America Biopharmaceutical CXO Market Share by Country (2019-2030)
 Figure 41. Mexico Biopharmaceutical CXO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 42. Brazil Biopharmaceutical CXO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 43. Middle East & Africa Biopharmaceutical CXO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 44. Middle East & Africa Biopharmaceutical CXO Market Share by Country (2019-2030)
 Figure 45. Turkey Biopharmaceutical CXO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 46. Saudi Arabia Biopharmaceutical CXO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 47. UAE Biopharmaceutical CXO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 48. Catalent Revenue Growth Rate in Biopharmaceutical CXO Business (2019-2024)
 Figure 49. Thermo Fisher Scientific Revenue Growth Rate in Biopharmaceutical CXO Business (2019-2024)
 Figure 50. Lonza Revenue Growth Rate in Biopharmaceutical CXO Business (2019-2024)
 Figure 51. Siegfried Revenue Growth Rate in Biopharmaceutical CXO Business (2019-2024)
 Figure 52. Recipharm Revenue Growth Rate in Biopharmaceutical CXO Business (2019-2024)
 Figure 53. Boehringer Ingelheim Revenue Growth Rate in Biopharmaceutical CXO Business (2019-2024)
 Figure 54. WuXi AppTech Revenue Growth Rate in Biopharmaceutical CXO Business (2019-2024)
 Figure 55. WuXi Biologics Revenue Growth Rate in Biopharmaceutical CXO Business (2019-2024)
 Figure 56. Fareva Revenue Growth Rate in Biopharmaceutical CXO Business (2019-2024)
 Figure 57. Samsung Biologics Revenue Growth Rate in Biopharmaceutical CXO Business (2019-2024)
 Figure 58. Aenova Revenue Growth Rate in Biopharmaceutical CXO Business (2019-2024)
 Figure 59. Delpharm Revenue Growth Rate in Biopharmaceutical CXO Business (2019-2024)
 Figure 60. Strides Pharma Revenue Growth Rate in Biopharmaceutical CXO Business (2019-2024)
 Figure 61. Piramal Revenue Growth Rate in Biopharmaceutical CXO Business (2019-2024)
 Figure 62. Famar Revenue Growth Rate in Biopharmaceutical CXO Business (2019-2024)
 Figure 63. Curia Revenue Growth Rate in Biopharmaceutical CXO Business (2019-2024)
 Figure 64. Jubilant Revenue Growth Rate in Biopharmaceutical CXO Business (2019-2024)
 Figure 65. Vetter Revenue Growth Rate in Biopharmaceutical CXO Business (2019-2024)
 Figure 66. AGC Pharma Chemicals Revenue Growth Rate in Biopharmaceutical CXO Business (2019-2024)
 Figure 67. Asymchem Revenue Growth Rate in Biopharmaceutical CXO Business (2019-2024)
 Figure 68. Pharmaron Revenue Growth Rate in Biopharmaceutical CXO Business (2019-2024)
 Figure 69. Eurofins Revenue Growth Rate in Biopharmaceutical CXO Business (2019-2024)
 Figure 70. Ascendia Pharmaceuticals Revenue Growth Rate in Biopharmaceutical CXO Business (2019-2024)
 Figure 71. Ardena Revenue Growth Rate in Biopharmaceutical CXO Business (2019-2024)
 Figure 72. CPL Revenue Growth Rate in Biopharmaceutical CXO Business (2019-2024)
 Figure 73. UPM Pharmaceuticals Revenue Growth Rate in Biopharmaceutical CXO Business (2019-2024)
 Figure 74. FUJIFILM Diosynth Biotechnologies Revenue Growth Rate in Biopharmaceutical CXO Business (2019-2024)
 Figure 75. Groupe Parima Revenue Growth Rate in Biopharmaceutical CXO Business (2019-2024)
 Figure 76. TBD Pharmatech Revenue Growth Rate in Biopharmaceutical CXO Business (2019-2024)
 Figure 77. Avid Bioservices Revenue Growth Rate in Biopharmaceutical CXO Business (2019-2024)
 Figure 78. NextPharma Revenue Growth Rate in Biopharmaceutical CXO Business (2019-2024)
 Figure 79. Alcami Revenue Growth Rate in Biopharmaceutical CXO Business (2019-2024)
 Figure 80. Societal CDMO Revenue Growth Rate in Biopharmaceutical CXO Business (2019-2024)
 Figure 81. MedPharm Revenue Growth Rate in Biopharmaceutical CXO Business (2019-2024)
 Figure 82. Euroapi Revenue Growth Rate in Biopharmaceutical CXO Business (2019-2024)
 Figure 83. BioVectra Revenue Growth Rate in Biopharmaceutical CXO Business (2019-2024)
 Figure 84. Pfizer CentreOne Revenue Growth Rate in Biopharmaceutical CXO Business (2019-2024)
 Figure 85. Fermion Revenue Growth Rate in Biopharmaceutical CXO Business (2019-2024)
 Figure 86. Bottom-up and Top-down Approaches for This Report
 Figure 87. Data Triangulation
 Figure 88. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Nano String

SIMILAR REPORTS

RELATED REPORTS

Global Pharma and Healthcare Social Media Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-14Y6812
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Food Additives Testing Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-34O3983
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Gabapentin API Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-9V17601
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Electronic Informed Consent Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-22C17047
Fri Sep 12 00:00:00 UTC 2025

Add to Cart